{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:13:05Z","timestamp":1795111985958,"version":"4.10.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hadassah-France Association KAHR Medical LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD47 is a cell surface ligand expressed on all nucleated cells. It is a unique immune checkpoint protein acting as \u201cdon\u2019t eat me\u201d signal to prevent phagocytosis and is constitutively overexpressed in many tumors. However, the underlying mechanism(s) for CD47 overexpression is not clear. Here, we show that irradiation (IR) as well as various other genotoxic agents induce elevated expression of CD47. This upregulation correlates with the extent of residual double-strand breaks (DSBs) as determined by \u03b3H2AX staining. Interestingly, cells lacking mre-11, a component of the MRE11-RAD50-NBS1 (MRN) complex that plays a central role in DSB repair, or cells treated with the mre-11 inhibitor, mirin, fail to elevate the expression of CD47 upon DNA damage. On the other hand, both p53 and NF-\u03baB pathways or cell-cycle arrest do not play a role in CD47 upregualtion upon DNA damage. We further show that CD47 expression is upregulated in livers harvested from mice treated with the DNA-damage inducing agent Diethylnitrosamine (DEN) and in cisplatin-treated mesothelioma tumors. Hence, our results indicate that CD47 is upregulated following DNA damage in a mre-11-dependent manner. Chronic DNA damage response in cancer cells might contribute to constitutive elevated expression of CD47 and promote immune evasion.<\/jats:p>","DOI":"10.1038\/s42003-023-04615-6","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T10:03:06Z","timestamp":1678183386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The DNA damage response pathway regulates the expression of the immune checkpoint CD47"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1810-170X","authenticated-orcid":false,"given":"Lucy","family":"Ghantous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Volman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hefez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Friehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Chajut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-5735","authenticated-orcid":false,"given":"Michal Dranitzki","family":"Elhalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7987","authenticated-orcid":false,"given":"Jacob","family":"Rachmilewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"4615_CR1","doi-asserted-by":"publisher","first-page":"14016","DOI":"10.1073\/pnas.0906549106","volume":"106","author":"KS Chan","year":"2009","unstructured":"Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016\u201314021 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4615_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.4049\/jimmunol.161.4.1853","volume":"161","author":"S Adams","year":"1998","unstructured":"Adams, S. et al. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J. Immunol. 161, 1853\u20131859 (1998).","journal-title":"J. Immunol."},{"key":"4615_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/386181a0","volume":"386","author":"A Kharitonenkov","year":"1997","unstructured":"Kharitonenkov, A. et al. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386, 181\u2013186 (1997).","journal-title":"Nature"},{"key":"4615_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nri1859","volume":"6","author":"AN Barclay","year":"2006","unstructured":"Barclay, A. N. & Brown, M. H. The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 6, 457\u2013464 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"4615_CR5","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","volume":"94","author":"M Seiffert","year":"1999","unstructured":"Seiffert, M. et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94, 3633\u20133643 (1999).","journal-title":"Blood"},{"key":"4615_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051\u20132054 (2000).","journal-title":"Science"},{"key":"4615_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"4615_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/bjc.2017.173","volume":"117","author":"L Barrera","year":"2017","unstructured":"Barrera, L. et al. CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br. J. Cancer 117, 385\u2013397 (2017).","journal-title":"Br. J. Cancer"},{"key":"4615_CR9","first-page":"2901","volume":"9","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am. J. Transl. Res. 9, 2901\u20132910 (2017).","journal-title":"Am. J. Transl. Res."},{"key":"4615_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1349-7006.1997.tb00356.x","volume":"88","author":"Y Nishiyama","year":"1997","unstructured":"Nishiyama, Y. et al. Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate. Jpn. J. Cancer Res. 88, 120\u2013128 (1997).","journal-title":"Jpn. J. Cancer Res."},{"key":"4615_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","volume":"10","author":"X Liu","year":"2017","unstructured":"Liu, X., Kwon, H., Li, Z. & Fu, Y. X. Is CD47 an innate immune checkpoint for tumor evasion? J. Hematol. Oncol. 10, 12 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"4615_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung, H. L., Szilagyi, K., Barclay, N. A. & van den Berg, T. K. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 276, 145\u2013164 (2017).","journal-title":"Immunol. Rev."},{"key":"4615_CR13","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4615_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"4615_CR15","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-10-0349","volume":"16","author":"M Nagahara","year":"2010","unstructured":"Nagahara, M. et al. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin. Cancer Res. 16, 4625\u20134635 (2010).","journal-title":"Clin. Cancer Res."},{"key":"4615_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0957-0","volume":"19","author":"J Yuan","year":"2019","unstructured":"Yuan, J. et al. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. Cancer Cell Int. 19, 238 (2019).","journal-title":"Cancer Cell Int."},{"key":"4615_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215 (2015).","journal-title":"Nat. Med."},{"key":"4615_CR18","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103\u201311108 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4615_CR19","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2004-07-2921","volume":"105","author":"S Beyth","year":"2005","unstructured":"Beyth, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214\u20132219 (2005).","journal-title":"Blood"},{"key":"4615_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.exphem.2006.11.001","volume":"35","author":"D Gur-Wahnon","year":"2007","unstructured":"Gur-Wahnon, D., Borovsky, Z., Beyth, S., Liebergall, M. & Rachmilewitz, J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp. Hematol. 35, 426\u2013433 (2007).","journal-title":"Exp. Hematol."},{"key":"4615_CR21","doi-asserted-by":"publisher","first-page":"e6846","DOI":"10.1371\/journal.pone.0006846","volume":"4","author":"D Gur-Wahnon","year":"2009","unstructured":"Gur-Wahnon, D., Borovsky, Z., Liebergall, M. & Rachmilewitz, J. The induction of APC with a distinct tolerogenic phenotype via contact-dependent STAT3 activation. PLoS ONE 4, e6846 (2009).","journal-title":"PLoS ONE"},{"key":"4615_CR22","doi-asserted-by":"publisher","first-page":"e75595","DOI":"10.1371\/journal.pone.0075595","volume":"8","author":"N Toledano","year":"2013","unstructured":"Toledano, N., Gur-Wahnon, D., Ben-Yehuda, A. & Rachmilewitz, J. Novel CD47: SIRPalpha dependent mechanism for the activation of STAT3 in antigen-presenting cell. PLoS ONE 8, e75595 (2013).","journal-title":"PLoS ONE"},{"key":"4615_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1753425919876690","volume":"26","author":"S Gholamin","year":"2020","unstructured":"Gholamin, S. et al. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Innate Immun. 26, 130\u2013137 (2020).","journal-title":"Innate Immun."},{"key":"4615_CR24","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/jitc-2020-000905","volume":"8","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. CD47\/SIRPalpha blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J. Immunother. Cancer 8, e000905 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4615_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23442-z","volume":"12","author":"Z Bian","year":"2021","unstructured":"Bian, Z. et al. Intratumoral SIRPalpha-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat. Commun. 12, 3229 (2021).","journal-title":"Nat. Commun."},{"key":"4615_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00542-9","volume":"18","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y., Yao, Y., Deng, Y. & Shao, A. Regulation of efferocytosis as a novel cancer therapy. Cell Commun. Signal 18, 71 (2020).","journal-title":"Cell Commun. Signal"},{"key":"4615_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ijc.28015","volume":"133","author":"DW Vermeer","year":"2013","unstructured":"Vermeer, D. W. et al. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int. J. Cancer 133, 120\u2013129 (2013).","journal-title":"Int. J. Cancer"},{"key":"4615_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3389\/fonc.2019.00994","volume":"9","author":"S Kaur","year":"2019","unstructured":"Kaur, S. et al. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. Front Oncol. 9, 994 (2019).","journal-title":"Front Oncol."},{"key":"4615_CR29","doi-asserted-by":"publisher","first-page":"3ra7","DOI":"10.1126\/scitranslmed.3000139","volume":"1","author":"JB Maxhimer","year":"2009","unstructured":"Maxhimer, J. B. et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci. Transl. Med. 1, 3ra7 (2009).","journal-title":"Sci. Transl. Med."},{"key":"4615_CR30","doi-asserted-by":"publisher","first-page":"24858","DOI":"10.1074\/jbc.M115.665752","volume":"290","author":"TW Miller","year":"2015","unstructured":"Miller, T. W. et al. CD47 receptor globally regulates metabolic pathways that control resistance to ionizing radiation. J. Biol. Chem. 290, 24858\u201324874 (2015).","journal-title":"J. Biol. Chem."},{"key":"4615_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep01038","volume":"3","author":"DR Soto-Pantoja","year":"2013","unstructured":"Soto-Pantoja, D. R., Ridnour, L. A., Wink, D. A. & Roberts, D. D. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci. Rep. 3, 1038 (2013).","journal-title":"Sci. Rep."},{"key":"4615_CR32","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/nar\/gkp237","volume":"37","author":"A Asaithamby","year":"2009","unstructured":"Asaithamby, A. & Chen, D. J. Cellular responses to DNA double-strand breaks after low-dose gamma-irradiation. Nucleic Acids Res. 37, 3912\u20133923 (2009).","journal-title":"Nucleic Acids Res."},{"key":"4615_CR33","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.1002213107","volume":"107","author":"S Grudzenski","year":"2010","unstructured":"Grudzenski, S., Raths, A., Conrad, S., Rube, C. E. & Lobrich, M. Inducible response required for repair of low-dose radiation damage in human fibroblasts. Proc. Natl Acad. Sci. USA 107, 14205\u201314210 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4615_CR34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nsmb.1639","volume":"16","author":"M Dinkelmann","year":"2009","unstructured":"Dinkelmann, M. et al. Multiple functions of MRN in end-joining pathways during isotype class switching. Nat. Struct. Mol. Biol. 16, 808\u2013813 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"4615_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nsmb.1641","volume":"16","author":"E Rass","year":"2009","unstructured":"Rass, E. et al. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat. Struct. Mol. Biol. 16, 819\u2013824 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"4615_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/nar\/gkp905","volume":"38","author":"EM Taylor","year":"2010","unstructured":"Taylor, E. M. et al. The Mre11\/Rad50\/Nbs1 complex functions in resection-based DNA end joining in Xenopus laevis. Nucleic Acids Res. 38, 441\u2013454 (2010).","journal-title":"Nucleic Acids Res."},{"key":"4615_CR37","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nsmb0809-798","volume":"16","author":"S Zha","year":"2009","unstructured":"Zha, S., Boboila, C. & Alt, F. W. Mre11: roles in DNA repair beyond homologous recombination. Nat. Struct. Mol. Biol. 16, 798\u2013800 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"4615_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm3047","volume":"12","author":"TH Stracker","year":"2011","unstructured":"Stracker, T. H. & Petrini, J. H. The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 12, 90\u2013103 (2011).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"4615_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1139\/O07-069","volume":"85","author":"RS Williams","year":"2007","unstructured":"Williams, R. S., Williams, J. S. & Tainer, J. A. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem. Cell Biol. 85, 509\u2013520 (2007).","journal-title":"Biochem. Cell Biol."},{"key":"4615_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.genet.40.110405.090451","volume":"40","author":"C Wyman","year":"2006","unstructured":"Wyman, C. & Kanaar, R. DNA double-strand break repair: all\u2019s well that ends well. Annu. Rev. Genet. 40, 363\u2013383 (2006).","journal-title":"Annu. Rev. Genet."},{"key":"4615_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.dnarep.2004.03.024","volume":"3","author":"O Fernandez-Capetillo","year":"2004","unstructured":"Fernandez-Capetillo, O., Lee, A., Nussenzweig, M. & Nussenzweig, A. H2AX: the histone guardian of the genome. DNA Repair (Amst.) 3, 959\u2013967 (2004).","journal-title":"DNA Repair (Amst.)"},{"key":"4615_CR42","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","volume":"18","author":"ND Lakin","year":"1999","unstructured":"Lakin, N. D. & Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene 18, 7644\u20137655 (1999).","journal-title":"Oncogene"},{"key":"4615_CR43","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1073\/pnas.87.5.1973","volume":"87","author":"B Bressac","year":"1990","unstructured":"Bressac, B. et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 87, 1973\u20131977 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4615_CR44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/carcin\/14.5.987","volume":"14","author":"IC Hsu","year":"1993","unstructured":"Hsu, I. C. et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987\u2013992 (1993).","journal-title":"Carcinogenesis"},{"key":"4615_CR45","doi-asserted-by":"crossref","unstructured":"Mitchell, J.K. et al. Hepatitis C virus indirectly disrupts DNA damage-induced p53 responses by activating protein kinase R. mBio 8, (2017).","DOI":"10.1128\/mBio.00121-17"},{"key":"4615_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/0008-5472.CAN-05-2234","volume":"66","author":"KJ Campbell","year":"2006","unstructured":"Campbell, K. J., Witty, J. M., Rocha, S. & Perkins, N. D. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res. 66, 929\u2013935 (2006).","journal-title":"Cancer Res."},{"key":"4615_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.20517\/2394-4722.2017.03","volume":"3","author":"W Wang","year":"2017","unstructured":"Wang, W., Mani, A. M. & Wu, Z. H. DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression. J. Cancer Metastasis Treat. 3, 45\u201359 (2017).","journal-title":"J. Cancer Metastasis Treat."},{"key":"4615_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian, A., Ahmadi, Y. & Yousefi, B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst.) 42, 63\u201371 (2016).","journal-title":"DNA Repair (Amst.)"},{"key":"4615_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316\u2013323 (2004).","journal-title":"Nature"},{"key":"4615_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nchembio.63","volume":"4","author":"A Dupre","year":"2008","unstructured":"Dupre, A. et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat. Chem. Biol. 4, 119\u2013125 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"4615_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2013.11.003","volume":"53","author":"A Shibata","year":"2014","unstructured":"Shibata, A. et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Mol. Cell 53, 7\u201318 (2014).","journal-title":"Mol. Cell"},{"key":"4615_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(00)81547-0","volume":"99","author":"GS Stewart","year":"1999","unstructured":"Stewart, G. S. et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99, 577\u2013587 (1999).","journal-title":"Cell"},{"key":"4615_CR53","doi-asserted-by":"publisher","first-page":"11141","DOI":"10.1158\/0008-5472.CAN-07-1369","volume":"67","author":"JS Kang","year":"2007","unstructured":"Kang, J. S., Wanibuchi, H., Morimura, K., Gonzalez, F. J. & Fukushima, S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res. 67, 11141\u201311146 (2007).","journal-title":"Cancer Res."},{"key":"4615_CR54","doi-asserted-by":"crossref","unstructured":"Geiger-Maor, A. et al. Macrophages regulate the systemic response to DNA damage by a cell non-autonomous mechanism. Cancer Res. 75, 2663\u20132673 (2015).","DOI":"10.1158\/0008-5472.CAN-14-3635"},{"key":"4615_CR55","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.18632\/aging.101120","volume":"8","author":"A Guedj","year":"2016","unstructured":"Guedj, A. et al. Early age decline in DNA repair capacity in the liver: in depth profile of differential gene expression. Aging (Albany NY) 8, 3131\u20133146 (2016).","journal-title":"Aging (Albany NY)"},{"key":"4615_CR56","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/gutjnl-2019-318491","volume":"69","author":"A Guedj","year":"2020","unstructured":"Guedj, A. et al. Gut microbiota shape \u2018inflamm-ageing\u2019 cytokines and account for age-dependent decline in DNA damage repair. Gut 69, 1064\u20131075 (2020).","journal-title":"Gut"},{"key":"4615_CR57","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4615_CR58","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3389\/fimmu.2019.01337","volume":"10","author":"X Shen","year":"2019","unstructured":"Shen, X. et al. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol. 10, 1337 (2019).","journal-title":"Front Immunol."},{"key":"4615_CR59","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186\u20131190 (2005).","journal-title":"Nature"},{"key":"4615_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).","journal-title":"Nat. Commun."},{"key":"4615_CR61","doi-asserted-by":"publisher","first-page":"109587","DOI":"10.1016\/j.celrep.2021.109587","volume":"36","author":"EC Suter","year":"2021","unstructured":"Suter, E. C. et al. Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation. Cell Rep. 36, 109587 (2021).","journal-title":"Cell Rep."},{"key":"4615_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/cimm.1998.1408","volume":"191","author":"J Rachmilewitz","year":"1999","unstructured":"Rachmilewitz, J., Riely, G. J. & Tykocinski, M. L. Placental protein 14 functions as a direct T-cell inhibitor. Cell Immunol. 191, 26\u201333 (1999).","journal-title":"Cell Immunol."},{"key":"4615_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle, R. et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci. Rep. 6, 22850 (2016).","journal-title":"Sci. Rep."},{"key":"4615_CR64","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li, J. H., Liu, S., Zhou, H., Qu, L. H. & Yang, J. H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92\u2013D97 (2014).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04615-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:18:59Z","timestamp":1678187939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04615-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4615"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04615-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ayelet Chajut is employed by KAHR Medical LTD and has options, and Michal Dranitzki Elhalel has a research fund, consultation fees, and options from KAHR Medical LTD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}